TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00934856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.
Study: NCT00901979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908A
Study: NCT00937521

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation III

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation IV

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation V

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine
Description: Vaccine candidate formulation VI

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Control
Description: Control

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal B vaccine with antipyretic
Description: Vaccine candidate formulation I with antipyretic
Study: NCT00901979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Study: NCT01483989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SYSTANE® Gel Drop lubricant eye gel
Description: SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
Study: NCT01135030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee
Description: Primary Total knee

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee
Description: Primary Total knee
Study: NCT02023905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: everolimus at 10 mg daily continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: everolimus at 10 mg daily continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: everolimus at 10 mg daily continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. TMZ will be stopped after 12 cycles
Study: NCT03195049

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood group,complete blood count
Description: measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood group,complete blood count
Description: measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion
Study: NCT02101658

Intervention type: OTHER
Intervention: clinic-based weight measurements
Study: NCT04573556

Intervention type: DRUG
Intervention: Lemborexant
Description: Lemborexant oral tablets.
Study: NCT02599493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
Study: NCT01675310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medical nutrition therapy + metformin

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical nutrition therapy
Description: medical nutrition therapy
Study: NCT00004445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRS-8
Study: NCT00968006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg once daily for 4 weeks
Study: NCT02719925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mg(+)
Description: * 1,5 L per day during 30 days~* No livestyle counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mg(-)
Description: 1,5 L water per day during 30 days No lifestyle counseling
Study: NCT00237211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT03946098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT
Description: A newly developed iCBT protocol targeting problem gambling.
Study: NCT00831012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3delta30/31-7164
Description: A live attenuated, recombinant DEN3 candidate vaccine virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3delta30/31-7164
Description: A live attenuated, recombinant DEN3 candidate vaccine virus
Study: NCT01200927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Perceptual motor therapy, comparing twice weekly to once weekly home program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Perceptual motor therapy, comparing twice weekly to once weekly home program
Study: NCT00716547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen in Diractin®
Description: 50 mg (b.i.d.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen in Diractin®
Description: 100 mg (b.i.d.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: 100 mg (b.i.d.)
Study: NCT02425241

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: pSG2.HIVconsv DNA vaccine
Description: pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pSG2.HIVconsv DNA vaccine
Description: pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ChAdV63.HIVconsv booster vaccine
Description: ChAdV63.HIVconsv 5 x 10\^10 vp at week 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv booster vaccine
Description: ChAdV63.HIVconsv 5 x 10\^10 vp at week 12.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MVA.HIVconsv booster vaccine
Description: MVA.HIVconsv 2 x 10\^8 pfu at week 20

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv booster vaccine
Description: MVA.HIVconsv 2 x 10\^8 pfu at week 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPHPC
Description: 40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
Study: NCT00142688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
Study: NCT00516828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: subcutaneously twice daily from Day 1 to 10
Study: NCT00871819

Intervention type: DEVICE
Group type: OTHER
Intervention: Precision Spinal Cord Stimulation (SCS)
Description: Various SCS device programming parameters
Study: NCT00631384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples VCT
Description: Offer women coming to antenatal clinics to have their husbands come with them for couples VCT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual VCT
Description: Women to receive individual VCT
Study: NCT00905359

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aperius™ PercLID™ System
Description: Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standalone Decompressive Surgery
Description: Lumbar decompressive surgery without instrumentation or fusion
Study: NCT00616330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin phosphate/butoconazole nitrate
Description: semi solid, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin phosphate
Description: semi solid, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: butoconazole nitrate
Description: semi solid, single dose
Study: NCT01003171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS-2 soft-gel capsule
Description: MCS-2 30 mg/day
Study: NCT04648098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge training and telephone counseling
Description: The discharge training was given by using different teaching methods in the form of verbal expression, demonstration, and question and answer. The care guide prepared by the researchers in line with the literature was used as a training material for stroke patients and their caregivers.The training varied according to the learning level of individuals but took an average of 40-60 minutes.~Consultation service was given to the caregivers one week after discharge and once a month for three months by telephone call.
Study: NCT04011423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unstable shoes plus Whole-body vibration
Description: Wearing unstable shoes during the whole-body vibration training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable shoes plus Whole-body vibration
Description: Wearing stable shoes during the whole-body vibration training
Study: NCT02442245

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: XSurge
Description: During part one of the study, 28 days of supplementation with XSurge will be provided. During the second part of the study 6 weeks of supplementation with XSurge will accompany a training program.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Microcrystalline Cellulose
Study: NCT02802319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Porcine Xenograft (Zcore)
Description: Ridge preservation bone grafting after tooth extraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bovine Xenograft (Bio-Oss)
Description: Ridge preservation bone grafting after tooth extraction
Study: NCT01184001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
Study: NCT02831309

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light-Intensity Condition
Description: The light-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, light--intensity activity breaks performed at 25% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Condition
Description: The moderate-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, moderate-intensity activity breaks performed at 50% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Condition
Description: The high-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, vigorous-intensity activity breaks performed at 75% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sedentary Condition
Description: The sedentary condition consisted of 8 hours of sitting interrupted with 2-minutes of screen time every 18 minutes. Standardized meals were provided.
Study: NCT01807221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Study: NCT02442245

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control: No supplementation
Study: NCT02812875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA-170
Description: Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma.~Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer.
Study: NCT02051569

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tryptophan
Description: Tryptophan and placebo are given in a crossover design, based on randomisation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tryptophan
Description: Tryptophan and placebo are given in a crossover design, based on randomisation.
Study: NCT00820664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Estrace 0.5 mg
Description: 0.5 mg tablet taken once daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Estrace 2 mg
Description: 2 mg tablets taken once daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo 0 mg capsule taken once daily for 28 days
Study: NCT02739776

Intervention type: DEVICE
Intervention: Thermographic imaging
Description: Using infrared-recording camera will obtain thermographic images of the lower extremities before and after the epidural blockade
Study: NCT00468130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Subjects under 40 kg will be started on 2.5mg per day of aripiprazole for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Inactive tablet made to resemble active tablet~Subjects under 40 kg will be started on 2.5mg per day of placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
Study: NCT00006010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT01031849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra
Description: Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.
Study: NCT02542423

Intervention type: OTHER
Group type: OTHER
Intervention: Endocan blood test samples
Study: NCT00742027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat hard gelatin capsules.
Study: NCT01911780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo matching amlodipine capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan + HCTZ
Description: FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan + HCTZ
Description: FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Description: capsule
Study: NCT03580499

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03988972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diathermy
Description: In women undergoing C.S, is healing power after diathermy equally to healing power after scalpel?

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: scalpel
Description: Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
Study: NCT03922204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-145
Description: full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-145
Description: full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda)
Description: Group B patients will be treated in combination with MCLA-145 and pembrolizumab 200mg Q3W.
Study: NCT06730789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epicondylitis bandage
Description: A conservative treatment method of lateral epicondylitis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist dorsiflexion splint
Description: A conservative treatment method of lateral epicondylitis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: A conservative treatment method of lateral epicondylitis